Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Science Blogs
ACI Profile for Alan Kotok
Featured in Alltop

Patent Set for Heart Tissue Regeneration Drug

A drug developed by MDI Biological Laboratory that stimulates growth of heart tissue to fix damage from heart attacks is scheduled to receive a U.S. patent. . . . → Read More: Patent Set for Heart Tissue Regeneration Drug

RNA Technology Licensed for Cystic Fibrosis Therapy

Two biotechnology companies are collaborating on treatments for cystic fibrosis that use genetic material to address underlying causes of the inherited disease. . . . → Read More: RNA Technology Licensed for Cystic Fibrosis Therapy

University Lab Spins-Off Fertility Testing Company

Katie Brenner (Bryce Richter, Univ. of Wisconsin-Madison)

29 April 2016. A new company is taking shape that aims to make it easier for women to get pregnant, based on research at a biochemistry lab at University of Wisconsin. BluDiagnostics, in Madison, founded by postdoctoral research Katie Brenner in the lab of biochemistry professor Douglas . . . → Read More: University Lab Spins-Off Fertility Testing Company

Biotechs to Develop Antibody Therapies, Explore Merger

Downtown Vancouver (Magnus Larsson, Flickr)

8 January 2016. Two biotechnology companies in Vancouver agreed to collaborate on developing antibody treatments for cancer, with an option to merge their enterprises later on. The deal calls for Zymeworks Inc. to make an undisclosed equity investment in Kairos Therapeutics Inc. Zymeworks is also receiving $US 61.5 million . . . → Read More: Biotechs to Develop Antibody Therapies, Explore Merger

Illumina Adds $40M for Genomic Accelerator Start-Ups

(Genome.gov)

26 February 2015. Illumina Inc., a developer of genomic analysis systems, is adding $40 million for investments in new enterprises based on genomic science that graduate from its accelerator program. The additional financing is provided by Viking Global Investors, an equity and hedge fund investment company in Greenwich, Connecticut.

The Illumina Accelerator program . . . → Read More: Illumina Adds $40M for Genomic Accelerator Start-Ups

Cancer Therapy Spin-Off Formed with $45M Funding

T-cell (NIAID/NIH)

22 January 2015. Autolus Ltd., a new enterprise developing engineered immune-system cells for treating cancer, is being formed in London, with £30 million ($45.4 million) in early financing. The company is founded and commercializing research by Martin Pule, a hematologist at University College London.

Pule, who serves as Autolus’s chief scientist, studies . . . → Read More: Cancer Therapy Spin-Off Formed with $45M Funding

Portfolio Model Proposed for Funding Alzheimer’s Research

(National Institute of Drug Abuse)

18 June 2014. Financial and biomedical researchers at Massachusetts Institute of Technology, University of California in Santa Barbara, and the biotechnology company Genentech outlined a different approach to funding research on Alzheimer’s disease that supports multiple simultaneous studies addressing various drug targets. The team led by MIT finance professor . . . → Read More: Portfolio Model Proposed for Funding Alzheimer’s Research

Investment Fund to Finance Global Health Technologies

Girls at a malaria prevention event in Ghana (USAID.gov)

A consortium of private sector, foundation, and government partners formed the Global Health Investment Fund, to finance higher-risk, late-stage development of vaccines and other public health innovations in low-income countries. The fund is led by the bank JPMorgan Chase and the Bill & Melinda Gates . . . → Read More: Investment Fund to Finance Global Health Technologies

Thermo Scientific Acquires Sequencing Technology Developer

(NIST.gov)

Thermo Fisher Scientific, a maker of laboratory instruments and technologies in Waltham, Massachusetts acquired the genomic sequencing systems developer Life Technologies in Carlsbad, California for $13.6 billion in cash and debt assumption. In the deal, Thermo Fisher Scientific will pay $76.00 per share and assume Life Technologies’ net outstanding debt, valued at $2.2 . . . → Read More: Thermo Scientific Acquires Sequencing Technology Developer

Kauffman CEO: New Venture Capital Structure Needed

Tom McDonnell (A. Kotok)

Kauffman Foundation CEO Tom McDonnell called for a new relationship between venture capital financiers and high-growth start-up enterprises to better reflect the long-term needs of these companies. McDonnell made the remarks in a speech on the state of entrepreneurship in the U.S. at the National Press Club in Washington, D.C. . . . → Read More: Kauffman CEO: New Venture Capital Structure Needed